Sec. 103. Penalties
111 words·~1 min read·
/bill/113/hr/3204/eh/section-103A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 301 ( 21 U.S.C. 331 ) is amended by adding at the end the following: The resale of a compounded drug that is labeled not for resale in accordance with section 503B. With respect to a drug to be compounded pursuant to section 503A or 503B, the intentional falsification of a prescription, as applicable. The failure to report drugs or adverse events by an entity that is registered in accordance with subsection
(b)of section 503B. . Section 502 ( 21 U.S.C. 352 ) is amended by adding at the end the following: If the advertising or promotion of a compounded drug is false or misleading in any particular. .
Connectionstraces to 2
Traces to 2 documents
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources